BTMD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

45.79M

-8.12%

0.020

-80%

47.51M

-3.03%

0.055

-85.14%

49.61M

+1.54%

0.070

-30%

Estimates Revision

The market is revising Downward the revenue expectations for biote Corp. (BTMD) for FY2025, with the revenue forecasts being adjusted by -0.41% over the past three months. During the same period, the stock price has changed by -9.79%.

Revenue Estimates for FY2025

Revise Downward

-0.41%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+12.5%

In Past 3 Month

Stock Price

Go Down

-9.79%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast BTMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BTMD is 3.67 USD with a low forecast of 3.00 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

3.00

Averages

3.67

High

4.50

Current: 0.000

Low

3.00

Averages

3.67

High

4.50

Truist

Buy

downgrade

$6 -> $5

2026-01-07

New

Reason

Truist

Price Target

$6 -> $5

2026-01-07

New

downgrade

Buy

Reason

Truist lowered the firm's price target on Biote to $5 from $6 and keeps a Buy rating on the shares. The affordable medicines theme remains attractive heading into 2026, the analyst tells investors in a research note.

B. Riley

Jeff Van Sinderen

Neutral

downgrade

$4 -> $3

2025-11-06

Reason

B. Riley

Jeff Van Sinderen

Price Target

$4 -> $3

2025-11-06

downgrade

Neutral

Reason

B. Riley analyst Jeff Van Sinderen lowered the firm's price target on Biote to $3 from $4 and keeps a Neutral rating on the shares. The firm reduced estimates post the Q3 report.

B. Riley

Buy -> Neutral

downgrade

$8 -> $4

2025-08-07

Reason

B. Riley

Price Target

$8 -> $4

2025-08-07

downgrade

Buy -> Neutral

Reason

B. Riley downgraded Biote to Neutral from Buy with a price target of $4, down from $8.

B. Riley

Jeff Van Sinderen

Buy -> Neutral

downgrade

$8 -> $4

2025-08-07

Reason

B. Riley

Jeff Van Sinderen

Price Target

$8 -> $4

2025-08-07

downgrade

Buy -> Neutral

Reason

B. Riley analyst Jeff Van Sinderen downgraded Biote to Neutral from Buy with a price target of $4, down from $8. The company reported a mixed Q2 and lowered its fiscal 2025 outlook, the analyst tells investors in a research note. The firm says a high attrition rate of established clinics, lower procedure volume, and a low rate of new clinic acquisition hindered Biote's Q2. Riley is unsure of the time it will take the company to achieve sustainable growth of quality new practitioner adds and procedures.

TD Cowen

Buy

downgrade

$6 -> $4

2025-05-09

Reason

TD Cowen

Price Target

$6 -> $4

2025-05-09

downgrade

Buy

Reason

TD Cowen lowered the firm's price target on Biote to $4 from $6 and keeps a Buy rating on the shares. The firm notes Q1 2025 upside was largely on better supplements growth and higher gross margin from both verticalization and favorable mix and management reiterated full year guide. TD Cowen notes that valuation remains inexpensive, but sees some bumps in the road before starting to see sustained growth. FY25 guide likely builds in conservatism but key to beats and raises will be the progress with new clinic growth, the firm adds.

B. Riley

Jeff Van Sinderen

Buy

downgrade

$9 -> $8

2025-05-09

Reason

B. Riley

Jeff Van Sinderen

Price Target

$9 -> $8

2025-05-09

downgrade

Buy

Reason

B. Riley analyst Jeff Van Sinderen lowered the firm's price target on Biote to $8 from $9 and keeps a Buy rating on the shares. The company's Q1 revenue and adjusted EBITDA came in above expectations, the analyst tells investors in a research note. The firm trimmed the price target to reflect a reduced multiple.

Valuation Metrics

The current forward P/E ratio for Biote Corp (BTMD.O) is 10.74, compared to its 5-year average forward P/E of 4.09. For a more detailed relative valuation and DCF analysis to assess Biote Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

4.09

Current PE

10.74

Overvalued PE

24.42

Undervalued PE

-16.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

2.30

Current EV/EBITDA

3.44

Overvalued EV/EBITDA

3.88

Undervalued EV/EBITDA

0.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

0.53

Current PS

0.41

Overvalued PS

0.85

Undervalued PS

0.22

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 221.99% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 221.99% over the last month.

Sold

Bought

BTMD News & Events

Events Timeline

No data

News

9.5

2025-11-06NASDAQ.COM

Biote Corp Reports Decrease in Q3 Earnings

9.0

2025-09-26NASDAQ.COM

Capricor (CAPR) Rises 5.3%: Could This Signal More Upside Ahead?

5.0

2025-06-09Newsfilter

Biote Names Rich Barrera to Board of Directors

People Also Watch

Frequently Asked Questions

What is Biote Corp (BTMD) stock price today?

The current price of BTMD is 2.58 USD — it has increased 1.98 % in the last trading day.

What is Biote Corp (BTMD)'s business?

biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.

What is the price predicton of BTMD Stock?

What is Biote Corp (BTMD)'s revenue for the last quarter?

Biote Corp revenue for the last quarter amounts to 47.96M USD, decreased -6.67 % YoY.

What is Biote Corp (BTMD)'s earnings per share (EPS) for the last quarter?

Biote Corp. EPS for the last quarter amounts to 0.22 USD, decreased -33.33 % YoY.

What changes have occurred in the market's expectations for Biote Corp (BTMD)'s fundamentals?

How many employees does Biote Corp (BTMD). have?

Biote Corp (BTMD) has 217 emplpoyees as of January 10 2026.

What is Biote Corp (BTMD) market cap?

Today BTMD has the market capitalization of 117.81M USD.